嵌合抗原受体
CD20
医学
淋巴瘤
抗体
安全概况
耐火材料(行星科学)
双特异性抗体
CD3型
免疫学
B细胞
肿瘤科
抗原
癌症研究
T细胞
内科学
单克隆抗体
CD8型
免疫系统
生物
不利影响
天体生物学
摘要
Abstract Bispecific antibodies have been successfully introduced into the management of relapsed or refractory B‐cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B‐cell lymphomas, and recent phase 2 studies confirm the favourable safety and show frequent and durable complete responses even in heavily pre‐treated and high‐risk patients. This paper discusses the future potential role of these new agents as single agents and in combinations, and their position in the current and future treatment landscape, also in relation to chimeric antigen receptor T‐cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI